公开(公告)号：US10596355B2

公开(公告)日：2020-03-24

申请号：US13173164

申请日：2011-06-30

申请人： Ralph A. Chappa

发明人： Ralph A. Chappa

IPC分类号： A61M25/10

摘要： A catheter assembly includes an expandable and collapsible structure having an outer surface. The expandable and collapsible structure is adapted to expand between a contracted state and a dilated state. A coating is disposed on the outer surface of the expandable and collapsible structure. The coating includes a bioactive agent. A sleeve is disposed over the coating. The sleeve is adapted to expand between a compressed state and an enlarged state and to return to the compressed state. The sleeve defines a plurality of openings in the compressed state. An outer diameter of the coating is less than an outer diameter of the sleeve when the expandable and collapsible structure is in the contracted state and greater than the outer diameter of the sleeve when the expandable and collapsible structure is in the dilated state.

公开(公告)号：US10524809B2

公开(公告)日：2020-01-07

申请号：US15053526

申请日：2016-02-25

申请人： SurModics, Inc.

发明人： Charlie Olson

IPC分类号： A61B17/22 ,  A61B17/3207 ,  A61M25/10 ,  A61B17/32 ,  A61B17/00

摘要： The disclosure provides plaque treatment catheter assemblies for the treatment of arterial plaques and removal of clots. One assembly includes a second catheter tube movable within a first catheter tube, and an expansion member movable within the second tube. The second catheter tube has one or more distally-disposed and outwardly-expandable plaque treatment portion(s). Another assembly includes a catheter tube and at least one channel(s) within the catheter. The channel includes an elongate member with a distally-disposed plaque scoring or clot retrieval member. Optionally, the assembly includes an expandable member that can cause movement of the scoring member.

公开(公告)号：US10478201B2

公开(公告)日：2019-11-19

申请号：US15053526

申请日：2016-02-25

申请人： SurModics, Inc.

发明人： Charlie Olson

IPC分类号： A61B17/22 ,  A61B17/3207 ,  A61M25/10 ,  A61B17/32 ,  A61B17/00

摘要： The disclosure provides plaque treatment catheter assemblies for the treatment of arterial plaques and removal of clots. One assembly includes a second catheter tube movable within a first catheter tube, and an expansion member movable within the second tube. The second catheter tube has one or more distally-disposed and outwardly-expandable plaque treatment portion(s). Another assembly includes a catheter tube and at least one channel(s) within the catheter. The channel includes an elongate member with a distally-disposed plaque scoring or clot retrieval member. Optionally, the assembly includes an expandable member that can cause movement of the scoring member.

公开(公告)号：US10391292B2

公开(公告)日：2019-08-27

申请号：US15620008

申请日：2017-06-12

申请人： Surmodics, Inc.

发明人： Gregg Stuart Sutton

IPC分类号： A61M39/00 ,  A61M39/02 ,  A61M39/06 ,  A61B17/00

摘要： Aspects herein relate to a medical device for providing a leak-resistant seal for use in a vascular access device. In various embodiments, a device for vascular access hemostasis is included. The device can include an enclosure configured to at least partially receive a medical device, the enclosure defining a cavity. The enclosure can have a first seal portion and a second seal portion, the cavity disposed between the first seal portion and the second seal portion. The enclosure can include the second seal portion comprising a split, septum seal. The enclosure can include a barrel in structural communication with the second seal portion. The device can include a constriction ring disposed around the barrel, the constriction ring interfacing with the second seal portion to limit movement of the split, septum seal.

公开(公告)号：US10315987B2

公开(公告)日：2019-06-11

申请号：US13316030

申请日：2011-12-09

申请人： Aleksey V. Kurdyumov

发明人： Aleksey V. Kurdyumov

IPC分类号： C07C275/38 ,  C07C27/28 ,  C07C271/28

摘要： Described herein is a linking agent that includes a polymeric or non-polymeric core molecule and one or more photoreactive groups covalently attached to the core molecule by one or more linking elements that include a urea linkage, a carbamate linkage, or a combination thereof.

公开(公告)号：US10253193B2

公开(公告)日：2019-04-09

申请号：US15994206

申请日：2018-05-31

申请人： Surmodics, Inc.

发明人： Aleksey V. Kurdyumov ,  Dale G. Swan

IPC分类号： C07F9/145 ,  C09D7/63 ,  A61L17/14 ,  A61L27/34 ,  A61L29/08 ,  A61L31/10 ,  C07F7/10 ,  C07F9/12 ,  C07F9/40 ,  C08F2/48 ,  C07F7/18 ,  C07F9/06 ,  C08K5/51 ,  C08K5/5419 ,  C08K5/544

摘要： Described herein is a degradable linking agent of formula Photo1-LG-Photo2, wherein Photo1 and Photo2 independently represent at least one photoreactive group and LG represents a linking group comprising one or more silicon atoms or one or more phosphorous atoms. The degradable linking agent includes a covalent linkage between at least one photoreactive group and the linking group, wherein the covalent linkage between at least one photoreactive group and the linking group is interrupted by at least one heteroatom. A method for coating a support surface with the degradable linking agent, coated support surfaces and medical devices are also described.

公开(公告)号：US09999675B2

公开(公告)日：2018-06-19

申请号：US15357496

申请日：2016-11-21

申请人： Surmodics, Inc.

发明人： Joseph Ventura ,  Shannon Wadman ,  Joram Slager ,  Joseph Schmidt McGonigle ,  Robert W. Hergenrother

IPC分类号： A61K31/337 ,  A61K47/34 ,  A61L27/18 ,  A61L27/54 ,  A61K9/08 ,  A61K9/00

CPC分类号： A61K47/34 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/337 ,  A61L27/18 ,  A61L27/54 ,  A61L2300/416 ,  A61L2300/63 ,  A61L2400/06 ,  C08L79/02

摘要： Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.

公开(公告)号：US09994721B2

公开(公告)日：2018-06-12

申请号：US15283818

申请日：2016-10-03

申请人： Surmodics, Inc.

发明人： Aleksey V. Kurdyumov ,  Dale G. Swan

IPC分类号： C07F7/10 ,  C09D7/12 ,  A61L17/14 ,  A61L27/34 ,  A61L29/08 ,  A61L31/10 ,  C07F7/18 ,  C07F9/12 ,  C07F9/145 ,  C07F9/40 ,  C08F2/48 ,  C07F9/06 ,  C08K5/51 ,  C08K5/5419 ,  C08K5/544

CPC分类号： C09D7/63 ,  A61L17/145 ,  A61L27/34 ,  A61L29/085 ,  A61L31/10 ,  A61L2400/18 ,  A61L2420/02 ,  C07F7/10 ,  C07F7/1804 ,  C07F7/184 ,  C07F9/06 ,  C07F9/12 ,  C07F9/145 ,  C07F9/4025 ,  C07F9/4084 ,  C08F2/48 ,  C08K5/51 ,  C08K5/5419 ,  C08K5/544 ,  C09D7/1233

摘要： Described herein is a degradable linking agent of formula Photo1-LG-Photo2, wherein Photo1 and Photo2 independently represent at least one photoreactive group and LG represents a linking group comprising one or more silicon atoms or one or more phosphorous atoms. The degradable linking agent includes a covalent linkage between at least one photoreactive group and the linking group, wherein the covalent linkage between at least one photoreactive group and the linking group is interrupted by at least one heteroatom. A method for coating a support surface with the degradable linking agent, coated support surfaces and medical devices are also described.

公开(公告)号：US09993441B2

公开(公告)日：2018-06-12

申请号：US14669571

申请日：2015-03-26

申请人： SurModics, Inc.

发明人： Joseph Schmidt McGonigle ,  Aleksey V. Kurdyumov ,  Jeffrey J. Missling ,  Nathan A. Lockwood ,  Kevin W. Burton ,  Beth A. Petersen

IPC分类号： A61F2/00 ,  A61K9/70 ,  A61K31/573 ,  A61K9/00 ,  A61K47/34 ,  A61L29/06 ,  A61L29/14 ,  A61L29/16 ,  A61L31/04 ,  A61F2/07 ,  A61F2/82 ,  A61L31/10

CPC分类号： A61K9/7007 ,  A61F2/07 ,  A61F2/82 ,  A61K9/0024 ,  A61K31/573 ,  A61K47/34 ,  A61L29/06 ,  A61L29/14 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L2300/404 ,  A61L2300/406 ,  C08L67/04

摘要： A biocompatible polymeric controlled release matrix barrier structure for delivery of one or more bioactive agents from an implantable medical device is described. In an embodiment, a biocompatible polymeric controlled release matrix barrier structure is included. The biocompatible polymeric controlled release matrix can include a body structure formed of a compliant material comprising one or more compliant biocompatible polymers and one or more bioactive agents. The body structure can define a central aperture through which a subcutaneous element of an implantable medical device passes. Other embodiments are included herein.

公开(公告)号：US09949957B2

公开(公告)日：2018-04-24

申请号：US15262465

申请日：2016-09-12

申请人： Surmodics, Inc.

发明人： Joram Slager

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K9/107 ,  A61K9/19 ,  A61K9/51 ,  A61L29/08 ,  A61L29/16 ,  A61K9/14 ,  A61K9/16

CPC分类号： A61K31/436 ,  A61K9/0019 ,  A61K9/1075 ,  A61K9/145 ,  A61K9/1688 ,  A61K9/19 ,  A61K9/5123 ,  A61K9/5138 ,  A61K9/5146 ,  A61L29/085 ,  A61L29/16 ,  Y02A50/402 ,  Y02A50/478 ,  Y10T428/2982

摘要： The disclosure provides macrolide particulates including a macrolide therapeutic agent such as rapamycin at high concentration in the particulate. In one method the particulates are made by adding a composition containing an polyoxyethylene sorbitan n-acyl ester, poly(ethyleneimine), or alkylated quaternary ammonium salt to a composition including macrolide dissolved in an alcohol such as ethanol. In another method the particulates are made by adding a non-solvent composition to a composition including macrolide and an alkyl-substituted chromanol dissolved in an alcohol such as ethanol. The formed macrolide particulates have one or more desirable properties including sizes in the range of 0.1 μm to 10 μm, spherical or near spherical shapes, low polydispersity, and/or stability. The macrolide particulates can be used for therapeutic compositions, or in association with an implantable or insertable medical device, such as associated with a polymeric coating on a device.